NCT06843447 2026-03-27
MK-5909-003
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT06014528 2025-04-30
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
InxMed (Shanghai) Co., Ltd.
Phase 2 Recruiting
NCT01332656 2015-12-21
OPSALIN
Sanofi
Phase 2 Completed
NCT01485848 2014-06-10
ESP2011-002
Esperance Pharmaceuticals Inc
Phase 2 Completed